LipoScience, Inc., a clinical diagnostic company, is engaged in the field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology in the United States. The company’s technology platform combines proprietary signal processing algorithms and NMR spectroscopic detection into a clinical analyzer to identify and quantify concentrations of lipoproteins and small molecule metabolites. It offers NMR LipoProfile test, which directly measures various low density lipoprotein (LDL) particles in a blood sample, and provides physicians and their patients with information to personalize management of risk for heart disease. LipoScience, Inc. sells its NMR LipoProfile test to clinic...
2500 Sumner Boulevard
Raleigh, NC 27616
Founded in 1994
LipoScience, Inc.(NasdaqGM:LPDX) dropped from NASDAQ Composite Index
Nov 23 14
LipoScience, Inc. will be removed from the NASDAQ Composite Index.
LipoScience, Inc. Announces Financial Results for the Third Quarter and Nine Months Ended September 30, 2014
Nov 12 14
LipoScience, Inc. announced financial results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenues of $8,562,000 against $12,738,000 a year ago. Loss from operations was $3,832,000 against $4,179,000 a year ago. Net loss was $4,260,000 against $4,627,000 a year ago. Net loss per basic and diluted share was $0.28 against $0.31 a year ago. Net cash used in operating activities was $1.9 million for the three months ended September 30, 2014, a decrease of $0.3 million from the same period last year.
For the nine months, the company reported revenues of $29,615,000 against $39,665,000 a year ago. Loss from operations was $9,070,000 against $8,506,000 a year ago. Net loss was $10,359,000 against $9,919,000 a year ago. Net loss per basic and diluted share was $0.68 against $0.67 a year ago. Net cash used in operating activities was $5,444,000 against $9,007,000 a year ago. Purchases of property and equipment were $4,525,000 against $2,939,000 a year ago. Capitalized patent and trademark costs were $48,000 against $154,000 a year ago.
LipoScience, Inc., Special/Extraordinary Shareholders Meeting, Nov 20, 2014
Nov 10 14
LipoScience, Inc., Special/Extraordinary Shareholders Meeting, Nov 20, 2014. Agenda: To consider and adopt the agreement and plan of merger.